Development of a Novel Therapeutic for Melioidosis
$456,766N01FY2025AINIH
An2 Therapeutics, Inc., Menlo Park CA
Investigators
Abstract
To support the advanced development of candidate therapeutics for biodefense pathogens or emerging infectious diseases. The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment.
View original record on NIH RePORTER →